Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) convened a Scientific Advisory Board on January 30, 2026 to align its Accum ADC strategy for improved intracellular payload delivery. Advisors with ADC chemistry, translational science, and partnering expertise informed prioritization of key experiments, data alignment for future clinical translation, and partnering readiness.

The SAB feedback is guiding a refined Accum ADC development roadmap aimed at enabling more effective, better-tolerated ADC therapies and positioning the platform for strategic collaborations.

News Market Reaction

-2.57%

1 alert

-2.57% News Effect

On the day this news was published, DTCFF declined 2.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum^® for antibody-drug conjugate ("ADC") applications.

The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum^®'s role in improving intracellular delivery of ADC payloads. The conversation focused on identifying the most critical scientific questions to address, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners.

"This was an exceptionally valuable discussion that helped us sharpen both our scientific focus and our strategic direction," said Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics. "The insights shared by our advisors are directly informing how we design our next studies, ensuring that we generate the data that matter most to advance Accum^® toward the clinic and position the platform for meaningful partnerships."

The discussion benefited from the complementary expertise of Rob Leanna, PhD, whose experience in ADC development, drug-linker chemistry, and clinical advancement was shaped through his long tenure at AbbVie; Danny Chui, PhD, who brought deep insight into ADC design and translational science informed by his significant work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics; and Brendan Hussey, PhD, who contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum^® development as the platform advances toward clinical translation and strategic partnerships.

As a result of this multidisciplinary dialogue, Defence Therapeutics is refining its Accum® ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum^®'s potential as a next-generation intracellular delivery solution for complex biologics. To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com.

About Defence Therapeutics:

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum^® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.

For further information:

Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282529

FAQ

What did Defence Therapeutics announce about the Accum ADC strategy on February 10, 2026 (DTCFF)?

They announced a Scientific Advisory Board meeting focused on Accum ADC strategy and development priorities. According to Defence Therapeutics, the SAB on January 30, 2026 refined the roadmap to align data generation with clinical and partner expectations to advance Accum toward translation.

Who advised Defence Therapeutics at the January 30, 2026 SAB meeting about Accum ADCs (DTCFF)?

The SAB included three advisors with ADC and partnering experience: Rob Leanna, Danny Chui, and Brendan Hussey. According to Defence Therapeutics, their combined expertise spans ADC chemistry, translational science, clinical development, and value-creation strategy.

How will the SAB guidance affect Accum ADC development timelines for Defence Therapeutics (DTCFF)?

The SAB guidance will refine study design and data priorities to support clinical translation and partnering readiness. According to Defence Therapeutics, the input is informing next studies to generate partner-relevant data and better position Accum for future clinical programs.

What scientific priorities did Defence Therapeutics identify for Accum ADCs after the SAB meeting (DTCFF)?

Priorities include critical experiments to validate intracellular delivery and to align data with clinical partner expectations. According to Defence Therapeutics, focus areas are refining experimental design, ADC chemistry choices, and translational endpoints that matter for partners and clinics.

How can potential partners contact Defence Therapeutics about Accum ADC collaboration opportunities (DTCFF)?

Potential partners can request meetings or explore opportunities via the company contact email provided. According to Defence Therapeutics, interested parties should contact info@defencetherapeutics.com to schedule discussions about Accum partnerships or collaboration.